Related Experiment Video
Updated: Aug 12, 2026

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method
Published on: September 10, 2017
Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity
R D Petty1, I A Cree, L A Sutherland
1Tumour Chemosensitivity Laboratory, University of Dundee, Ninewells Hospital and Medical School, Scotland.
Abstract:
Many cytotoxic agents act by causing DNA damage, and the p53 tumour suppressor gene is known to be involved in the cellular response to DNA damage. Since inactivation of p53 is common in many tumours, we wondered if this would affect the sensitivity of cancer cells to cytotoxic agents. We have shown that this is indeed the case in transformed mouse cell lines with and without a mutated p53 gene; p53 "knockout" mouse fibroblasts, and normal human skin fibroblasts treated with an anti-sense p53 oligonucleotide. In addition, we have demonstrated a correlation between p53 protein expression in human breast cancer specimens and their chemosensitivity. The results show that inactivation or mutation of p53 renders cells more sensitive to those cytotoxic drugs whose primary mechanism of action is DNA damage.
Insights
Cancer cells with inactivated p53 tumor suppressor gene show increased sensitivity to DNA-damaging cytotoxic drugs. This finding has implications for cancer treatment strategies involving chemotherapy.
Area of Science:
- Molecular Biology
- Cancer Research
- Genetics
Background:
- The p53 tumor suppressor gene plays a critical role in cellular responses to DNA damage.
- Inactivation or mutation of the p53 gene is a frequent event in many human cancers.
- Understanding the role of p53 in drug sensitivity is crucial for developing effective cancer therapies.
Purpose of the Study:
- To investigate the impact of p53 gene status on the sensitivity of cancer cells to cytotoxic agents.
- To explore the correlation between p53 protein expression and chemosensitivity in human breast cancer specimens.
Main Methods:
- Utilized transformed mouse cell lines with and without mutated p53.
- Employed p53 knockout mouse fibroblasts.
- Treated normal human skin fibroblasts with an anti-sense p53 oligonucleotide.
- Analyzed p53 protein expression in human breast cancer tissues.
Main Results:
- Cells with inactivated or mutated p53 demonstrated heightened sensitivity to cytotoxic drugs that induce DNA damage.
- A significant correlation was observed between p53 protein expression levels and chemosensitivity in human breast cancer samples.
- p53 inactivation renders cancer cells more susceptible to DNA-damaging chemotherapy.
Conclusions:
- Inactivation or mutation of the p53 tumor suppressor gene enhances cancer cell sensitivity to DNA-damaging cytotoxic agents.
- p53 status is a potential predictive biomarker for chemosensitivity in cancer treatment.
- Targeting p53 or exploiting its inactivation could represent a therapeutic strategy to improve chemotherapy efficacy.
Related Concept Videos
Negative Regulator Molecules
DNA Damage can Stall the Cell Cycle
Abnormal Proliferation
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
DNA Damage Can Stall the Cell Cycle

